Sotagliflozin bulk supplier for pharma manufacturers

Sotagliflozin 200 mg, 40mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200 mg, 40mg

Reference Brands: Inpefa (USA), Zynquista (EU)

Category: Diabetes

Sotagliflozin is an oral dual SGLT-1 and SGLT-2 inhibitor that helps lower blood glucose and reduces the risk of heart-failure related events. It is used in adults with type 2 diabetes and those with heart failure to improve cardiovascular outcomes.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Sotagliflozin — third party manufacturing & bulk supply

Sotagliflozin 200 mg, 40mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sotagliflozin is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sotagliflozin listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sotagliflozin →

Back to Listing

Frequently Asked Questions

Sotagliflozin is used for improving blood glucose control in adults with type 1 diabetes (as an adjunct to insulin) and type 2 diabetes in some regions. It works by inhibiting both SGLT1 and SGLT2 transporters, reducing glucose absorption in the intestine and increasing glucose excretion through urine.

Sotagliflozin is made from the active ingredient sotagliflozin, a dual sodium–glucose cotransporter inhibitor that blocks SGLT1 in the gut and SGLT2 in the kidneys.

A well-known trade name for Sotagliflozin is Zynquista.

Zynquista was developed by Lexicon Pharmaceuticals in collaboration with Sanofi. In some regions, rights have been managed directly by Lexicon following partnership changes.

The generic name is sotagliflozin.

The brand name is Zynquista.

Sotagliflozin is manufactured in facilities authorized by Lexicon Pharmaceuticals and its regional partners, with production occurring in the United States and Europe depending on regulatory approvals and supply chains.